TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00587808

Intervention type: PROCEDURE
Intervention: RHC with VO2 consumption
Description: All pressure-volume data is acquired at 250 Hz and stored on the Leycom system for offline analysis. Volume data will be calibrated using the most recent EF from echocardiogram and stroke volume from the Fick method. Measured O2 consumption will be utilized along with sampling of SVC and arterial blood oximetry to determine cardiac output at rest and during exercise

Intervention type: PROCEDURE
Intervention: RHC with VO2 consumption
Description: All pressure-volume data is acquired at 250 Hz and stored on the Leycom system for offline analysis. Volume data will be calibrated using the most recent EF from echocardiogram and stroke volume from the Fick method. Measured O2 consumption will be utilized along with sampling of SVC and arterial blood oximetry to determine cardiac output at rest and during exercise
Study: NCT02229825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule
Study: NCT03797963

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PBM+ACB
Description: Maxillary sinus floor elevation and bone grafting with the use of porcine bone mineral biomaterial (Symbios Xenograft) combined with autogenous cortical bone

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABB+ACB
Description: Maxillary sinus floor elevation and bone grafting with the use of anorganic bovine bone biomaterial (BioOss Xenograft) combined with autogenous cortical bone
Study: NCT03634098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: new quantitative imaging techniques with contast products
Description: magnetic resonance +/- Primovist and ultrafast ultrasound UFUS +Sonovue

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: new quantitative imaging techniques with contast products
Description: magnetic resonance +/- Primovist and ultrafast ultrasound UFUS +Sonovue

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood sample
Description: extensive clinical-biological phenotyping data; and / or data obtained by different omic approaches (metabolomics, targeted genetics, transcriptomics). Extracellular vesicle and immune cell profiling will complement this data

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: second generation tests
Description: second generation tests NIT-NASHr et NIT-A2F2
Study: NCT01500785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levosimendan
Description: infusion; levosimendan (12 μg/kg) The study drug will be administered together with the induction of cardioplegia solution during five minutes (=once for each patient)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin B 12
Description: Infusion made of Glucos B.Braun 50 mg/ml infusion together with vitamin B12 which is used to colour the glucose infusion to look identical to Simdax infusion The placebo will be administered together with the induction of cardioplegia solution during five minutes (=once for each patient).
Study: NCT00292045

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 protein/CpG 7909
Description: Patients received vaccinations consisting of the NY-ESO-1 protein (100 µg) combined with CpG 7909 (2.5 mg) as an adjuvant administered intradermally every 3 weeks for 4 doses (i.e., 12-week cycle).
Study: NCT04281420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-019
Description: ATG-019 30 mg QoD×3 is selected as the staring dose. Oral ATG-019 will be taken three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28-day cycle.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ATG-019 + Niacin ER
Description: ATG-019 60 mg is selected as starting dose. Oral ATG-019 will be taken three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28-day cycle. And a starting dose of 500 mg niacin ER (may be titrated up to 1,000 mg of daily dose, per label) co-administered with each dose of ATG-019.
Study: NCT03623386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PD neurofeedback
Description: PD-neurofeedback subjects will practice motor imagery in the MRI scanner and receive neurofeedback on their performance. There will be a total of 10-12 neurofeedback sessions on two separate days. Subjects will continue practicing motor imagery at home every day throughout the study period for 4-6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PD control
Description: PD-control subjects will practice visual imagery (e.g., of scenery, objects, etc., but not of movement) in the MRI scanner and will not receive neurofeedback on their performance. Subjects will continue practicing visual imagery at home every day throughout the study period for 4-6 weeks.
Study: NCT03188666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2477
Description: Pharmaceutical form: liquid product for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment periods 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Pharmaceutical form: Liquid product for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment period 1 only.
Study: NCT03008876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: infants receive acetaminophen for treatment of their PDA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: infants receive ibuprofen, standard of care in our unit, for treatment of a PDA
Study: NCT02903719

Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine
Description: All included patients with a right sided shoulder pain score on a numeric rating scale (NRS) equal to or above 6 and without postoperative exclusion criteria will have two (1st and 2nd intervention) ultrasound guided phrenic nerve blocks performed.

Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine
Description: All included patients with a right sided shoulder pain score on a numeric rating scale (NRS) equal to or above 6 and without postoperative exclusion criteria will have two (1st and 2nd intervention) ultrasound guided phrenic nerve blocks performed.
Study: NCT04120090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low dose ruxolitinib
Description: The dose for adult patients(Age\>=14 years) is generally 10 mg twice daily. For children(Age\<14 years ,weight \>=25kg),the dose was generally 5mg twice daily. For children(Age\<14 years, weight \<25kg), the dose was generally 2.5mg twice daily.
Study: NCT03462641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumazenil
Description: 1mg in 10cc normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumazenil
Description: 1mg in 10cc normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 10 cc normal saline
Study: NCT04120090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose ruxolitinib
Description: The dose for adult patients(Age\>=14 years) is generally 20mg twice daily. For children(Age\<14 years ,weight \>=25kg),the dose was generally 10mg twice daily. For children(Age\<14 years, weight \<25kg), the dose was generally 5mg twice daily
Study: NCT04060043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: The Pepti 10.8mg (goserelin acetate) implant is supplied as a cylindrical rod of biodegradable and biocompatible D, L Lactic and glycolic acids copolymer. Each implant contains goserelin acetate equivalent to 10.8mg of goserelin as well as a blend of high and low molecular weight range of D, L lactic and glycolic acids copolymer to total a weight of approximately 36.0mg per depot. The implant will be injected subcutaneously through the patient's anterior abdominal wall.
Study: NCT06137690

Intervention type: DEVICE
Intervention: other antifungal agents,breathing machine
Description: If treatment failure for patients in group A and group B，change other antifungal agents (Amphotericin B for Injection, 25mg, North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®). Mechanical ventilation (EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.

Intervention type: DEVICE
Intervention: other antifungal agents,breathing machine
Description: If treatment failure for patients in group A and group B，change other antifungal agents (Amphotericin B for Injection, 25mg, North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®). Mechanical ventilation (EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.
Study: NCT03837743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DUR-928 Topical Solution
Description: Topical solution containing active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Topical Solution
Description: Topical solution containing no active drug
Study: NCT03956810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: On-demand transportation
Description: On-demand scheduling via telephone, web portal, or the broker's mobile application.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual transportation
Description: Usual transportation scheduling via call-center.
Study: NCT04258475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir standard dosage of 1200 mg (two 600 mg tablets) orally once daily.
Description: Raltegravir will be dosed in a fasted state in all periods. Participants will take Raltegravir along with other ART medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium carbonate antacid tablet
Description: PK analysis of different doses of calcium carbonate antacid in patients undergoing ART treatment for HIV using Raltegravir.
Study: NCT02302547

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triple therapy
Description: Dosage treatment and usual prescription

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dual therapy
Description: 1 tablet (200mg/245mg) daily for 48 weeks
Study: NCT00106340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin
Study: NCT03462641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 10 cc normal saline
Study: NCT03974126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 40 grams of starch
Description: 40 grams of starch in form of white bread to be consumed within 15 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 80 grams of starch
Description: 80 grams of starch in form of white bread to be consumed within 15 minutes
Study: NCT01570517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IASD System
Description: Implantation of the DC Devices Inc. IASD System
Study: NCT02205268

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Near infrared spectroscopy neurofeedback training
Study: NCT01222988

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Optifast Products
Description: Optional Optifast products offered once every other week X 6 months; then monthly.
Study: NCT00920361

Intervention type: DRUG
Intervention: Follitropin beta
Description: Normally, Follistim Injection 150 or 225 IU will be administered (s.c. or i.m.) once a day for 4 days as follitropin beta (genetical recombination). The dosage will be adapted to growth of follicles (75-375 IU for 6-12 days, in general). If more than 3 follicles of mean diameter 16-20 mm are confirmed by ultrasound tomography, ovulation will be stimulated by using Human Chorionic Gonadotropin (hCG) drugs.
Study: NCT04080492

Intervention type: OTHER
Intervention: QOL Survey
Description: The Cardiac Quality of Life (QOL) survey measures health status in five domains: global, physical, emotional, social, and spiritual health. It also includes questions that assess self-efficacy and resilience. The global section asks about your overall quality of life and satisfaction with health. The physical section asks about symptoms and difficulty performing day-to-day tasks. The emotional section asks about depression, anxiety, and stress. The social section asks about social support and relationships. The spiritual section asks about the spiritual outlook on the burden of heart disease. Responses on a 5-level scale.

Intervention type: OTHER
Intervention: QOL Survey
Description: The Cardiac Quality of Life (QOL) survey measures health status in five domains: global, physical, emotional, social, and spiritual health. It also includes questions that assess self-efficacy and resilience. The global section asks about your overall quality of life and satisfaction with health. The physical section asks about symptoms and difficulty performing day-to-day tasks. The emotional section asks about depression, anxiety, and stress. The social section asks about social support and relationships. The spiritual section asks about the spiritual outlook on the burden of heart disease. Responses on a 5-level scale.
Study: NCT04351932

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bone marrow & adipose mesenchymal stem cells injection
Description: intrarticular bone marrow and adipose stem cells injection.
Study: NCT03862222

Intervention type: OTHER
Intervention: Contrast Sensitivity
Description: Participants will complete a task evaluating contrast sensitivity

Intervention type: OTHER
Intervention: Contrast Sensitivity
Description: Participants will complete a task evaluating contrast sensitivity

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological Evaluation
Description: Neuropsychological evaluation will be completed, including testing in domains of memory, executive function, visuospatial ability, language, processing speed. Results will be used for research purposes only.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological Evaluation
Description: Neuropsychological evaluation will be completed, including testing in domains of memory, executive function, visuospatial ability, language, processing speed. Results will be used for research purposes only.
Study: NCT04469088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Twenty-three patients with TJD will be allocated in Dry Needling Group. They will receive 3 sessions of dry needling separated for 4 days. This treatment will consist of puncturing the active myofascial trigger points (PGM) of the aforementioned muscles. Sterile acupuncture needles of 0.26 mm in diameter by 40 mm in length, guided with a plastic cannula of the Ener-qi brand, will be used. The area will be cleaned with alcohol and a deep puncture of the PGM will be performed, triggering local spasm responses. Needle through the muscle following the technique described by Hong (Hong et al. 1994). After the procedure, the area is compressed with cotton for 90 seconds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy Treatment
Description: Twenty-three patients will be allocated in Manual Therapy (MT) Group for three sessions during 30 minutes. MT treatment will consist in the application of neuromuscular techniques of the temporal, masseter and sternocleidomastoid muscles and Jones techniques in the external pterygoid muscle. Neuromuscular techniques are performed with the index and major fingers to apply a transverse friction with enough pressure to feel vertical fibers of each muscle or produce a medium discomfort level. To perform the Jones technique on the external pterygoid muscle, the patient will be asked to open the mouth and deviate the jaw slightly towards the treated side in order to make room for the finger to be located between the upper jaw and the coronoid process. Once the trigger point is located, we press to trigger the pain and we look for neurological silence and we maintain the pressure for 90 seconds. Over time, we slowly withdraw the pressure and return to the position passively.
Study: NCT03632460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injection [Precedex]
Description: epidural administration of dexmedetomidine added to ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injection [Precedex]
Description: epidural administration of dexmedetomidine added to ropivacaine
Study: NCT03998800

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement
Description: Dietary Supplement: L-arginine and L-citrulline supplement, L-arginine supplement, or placebo supplement (corn-starch) Subjects will complete 3 individual 10 day supplementation periods, separated by washout periods of approximately 2 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement
Description: Dietary Supplement: L-arginine and L-citrulline supplement, L-arginine supplement, or placebo supplement (corn-starch) Subjects will complete 3 individual 10 day supplementation periods, separated by washout periods of approximately 2 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Supplement
Description: Dietary Supplement: L-arginine and L-citrulline supplement, L-arginine supplement, or placebo supplement (corn-starch) Subjects will complete 3 individual 10 day supplementation periods, separated by washout periods of approximately 2 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance exercise on a cycle ergometer
Description: On day 10 of each supplementation period, subjects will complete a performance test on a cycle ergometer to investigate their endurance performance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance exercise on a cycle ergometer
Description: On day 10 of each supplementation period, subjects will complete a performance test on a cycle ergometer to investigate their endurance performance.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Endurance exercise on a cycle ergometer
Description: On day 10 of each supplementation period, subjects will complete a performance test on a cycle ergometer to investigate their endurance performance.
Study: NCT04715841

Intervention type: OTHER
Intervention: gait assessment
Description: gait assessment were done using 3DMA system

Intervention type: OTHER
Intervention: gait assessment
Description: gait assessment were done using 3DMA system
Study: NCT04224233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based physical activity programme
Description: iLiFE is a 12-week individualised programme, adapted to the participants' needs and preferences. This programme will be conducted in participants' home and include everyday tasks to train endurance, balance, flexibility and strength. The intervention incudes face-to-face sessions and phone calls. Face-to-face sessions aim to adapt activities to everyday tasks, increase frequency and/or intensity, monitor progress, clarify doubts, motivate higher daily energy expenditure and manage expectations. Phone-calls aim to clarify doubts and to monitor patients' motivation/evolution, following a motivational interview. At the start of the program, the physiotherapist will be present at all sessions, but these face-to-face visits will decrease over time. Patients will also receive a personalised manual (iLiFE manual) with activities to do in their everyday tasks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will receive a leaflet with exercises and PA recommendations.
Study: NCT00222755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disease Management
Description: Self-management, care management, guidelines
Study: NCT04154384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Care Specialist (LCS) Intervention
Description: The Life Care Specialist (LCS) uses a two-arm approach to education by initially assessing participants general understanding of opioids upon which targeted education is tailored and applied and secondly, building a longitudinal relationship with each patient to increase the saliency of administered opioid education during postoperative follow-up. Information includes proper disposal, common symptoms of opioid use, signs of dependence and overdose and use of naloxone. Information is disseminated orally with adjunct physical resource guides including visual representations and literature.